127 related articles for article (PubMed ID: 37950860)
1. Thrombopoietin mimetic-induced bone marrow fibrosis.
Harper K; Bagot C; Leach M; Bain BJ
Am J Hematol; 2024 Jan; 99(1):135-136. PubMed ID: 37950860
[No Abstract] [Full Text] [Related]
2. Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis.
Teofili L; Giona F; Martini M; Torti L; Cenci T; Foà R; Leone G; Larocca LM
J Clin Oncol; 2010 Jul; 28(19):e317-8. PubMed ID: 20516451
[No Abstract] [Full Text] [Related]
3. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
Wagner-Ballon O; Pisani DF; Gastinne T; Tulliez M; Chaligné R; Lacout C; Auradé F; Villeval JL; Gonin P; Vainchenker W; Giraudier S
Blood; 2007 Jul; 110(1):345-53. PubMed ID: 17374740
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.
Boiocchi L; Orazi A; Ghanima W; Arabadjief M; Bussel JB; Geyer JT
Mod Pathol; 2012 Jan; 25(1):65-74. PubMed ID: 21841770
[TBL] [Abstract][Full Text] [Related]
5. Romiplostim-induced myelofibrosis.
Rashidi A; Roullet MR
Blood; 2013 Sep; 122(12):2001. PubMed ID: 24175353
[No Abstract] [Full Text] [Related]
6. Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis.
Evrard S; Bluteau O; Tulliez M; Rameau P; Gonin P; Zetterberg E; Palmblad J; Bonnefoy A; Villeval JL; Vainchenker W; Giraudier S; Wagner-Ballon O
Blood; 2011 Jan; 117(1):246-9. PubMed ID: 20944070
[TBL] [Abstract][Full Text] [Related]
7. [Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia].
Kirito K; Komatsu N
Rinsho Ketsueki; 2013 Mar; 54(3):295-9. PubMed ID: 23676646
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.
Ghanima W; Geyer JT; Lee CS; Boiocchi L; Imahiyerobo AA; Orazi A; Bussel JB
Haematologica; 2014 May; 99(5):937-44. PubMed ID: 24463212
[TBL] [Abstract][Full Text] [Related]
9. Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis.
Akiyama T; Matsunaga T; Terui T; Miyanishi K; Tanaka I; Sato T; Kuroda H; Takimoto R; Takayama T; Kato J; Yamauchi N; Kogawa K; Sakamaki S; Hirayama Y; Kohda K; Niitsu Y
Leukemia; 2005 Sep; 19(9):1558-66. PubMed ID: 16034467
[TBL] [Abstract][Full Text] [Related]
10. Myelofibrosis: experimental models and human studies.
Taskin AL; Cohen-Solal K; Le Couedic JP; Abina MA; Villeval JL; Debili N; Casadevall N; Vainchenker W; Wendling F
Stem Cells; 1998; 16 Suppl 2():155-64. PubMed ID: 11012187
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin-responsive essential thrombocythaemia with myelofibrosis.
Ozaki S; Kosaka M; Ozaki K; Wakatsuki S; Hashimoto T; Miyazaki H
Br J Haematol; 1997 May; 97(2):449-52. PubMed ID: 9163612
[TBL] [Abstract][Full Text] [Related]
12. Rescue of a primary myelofibrosis model by retinoid-antagonist therapy.
Hong SH; Dvorak-Ewell M; Stevens HY; Barish GD; Castro GL; Nofsinger R; Frangos JA; Shoback D; Evans RM
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):18820-5. PubMed ID: 24191050
[TBL] [Abstract][Full Text] [Related]
13. Progression of romiplostim myelofibrosis to myeloproliferative neoplasm.
Dadfarnia T; Lee S
Blood; 2014 Mar; 123(13):1987. PubMed ID: 24800303
[No Abstract] [Full Text] [Related]
14. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation.
Yan XQ; Lacey D; Hill D; Chen Y; Fletcher F; Hawley RG; McNiece IK
Blood; 1996 Jul; 88(2):402-9. PubMed ID: 8695786
[TBL] [Abstract][Full Text] [Related]
15. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice.
Ulich TR; del Castillo J; Senaldi G; Kinstler O; Yin S; Kaufman S; Tarpley J; Choi E; Kirley T; Hunt P; Sheridan WP
Blood; 1996 Jun; 87(12):5006-15. PubMed ID: 8652813
[TBL] [Abstract][Full Text] [Related]
16. Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report.
Kim HY; Park SW; Kim JH; Kang JH; Lee WS; Song HN
Medicine (Baltimore); 2019 Jun; 98(25):e15882. PubMed ID: 31232923
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation.
Nagahisa H; Nagata Y; Ohnuki T; Osada M; Nagasawa T; Abe T; Todokoro K
Blood; 1996 Feb; 87(4):1309-16. PubMed ID: 8608219
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia.
Elliot MA; Yoon SY; Kao P; Li CY; Tefferi A
Eur J Haematol; 2002 Mar; 68(3):175-9. PubMed ID: 12068799
[TBL] [Abstract][Full Text] [Related]
19. The Role of Megakaryocytes in Myelofibrosis.
Melo-Cardenas J; Migliaccio AR; Crispino JD
Hematol Oncol Clin North Am; 2021 Apr; 35(2):191-203. PubMed ID: 33641863
[TBL] [Abstract][Full Text] [Related]
20. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
